{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["82(5)"],"submitter":["Zimmer JA"],"pubmed_abstract":["<h4>Importance</h4>Amyloid-related imaging abnormalities (ARIA) are the major adverse event associated with amyloid-targeting immunotherapy. Identifying clinical features and individual risk factors for ARIA could facilitate effective prediction and prevention strategies.<h4>Objective</h4>To characterize ARIA in participants treated with donanemab.<h4>Design, setting, and participants</h4>These prespecified and post hoc exploratory analyses use data from the placebo-controlled portions of the TRAILBLAZER-ALZ and ALZ 2 randomized clinical trials, conducted from December 2017 to December 2020 and from June 2020 to April 2023, respectively. Additional analyses are included from a stand-alone open-label addendum conducted from August 2021 through August 2023. Participants in the placebo-contro"],"journal":["JAMA neurology"],"pagination":["461-469"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11894547"],"repository":["biostudies-literature"],"pubmed_title":["Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease: Secondary Analysis of the TRAILBLAZER-ALZ and ALZ 2 Randomized Clinical Trials."],"pmcid":["PMC11894547"],"pubmed_authors":["Salloway S","Lauzon S","Battioui C","Brooks DA","Khanna R","Sims JR","Ardayfio P","Wang H","Zimmer JA","Andersen S","Nery ESM","Svaldi D","Lu M","Evans CD","Biffi A","Greenberg SM","Sperling RA","Engle SE","Sparks J","Mintun M"],"additional_accession":[]},"is_claimable":false,"name":"Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease: Secondary Analysis of the TRAILBLAZER-ALZ and ALZ 2 Randomized Clinical Trials.","description":"<h4>Importance</h4>Amyloid-related imaging abnormalities (ARIA) are the major adverse event associated with amyloid-targeting immunotherapy. Identifying clinical features and individual risk factors for ARIA could facilitate effective prediction and prevention strategies.<h4>Objective</h4>To characterize ARIA in participants treated with donanemab.<h4>Design, setting, and participants</h4>These prespecified and post hoc exploratory analyses use data from the placebo-controlled portions of the TRAILBLAZER-ALZ and ALZ 2 randomized clinical trials, conducted from December 2017 to December 2020 and from June 2020 to April 2023, respectively. Additional analyses are included from a stand-alone open-label addendum conducted from August 2021 through August 2023. Participants in the placebo-contro","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 May","modification":"2026-06-02T19:18:29.235Z","creation":"2025-04-04T02:51:00.909Z"},"accession":"S-EPMC11894547","cross_references":{"pubmed":["40063015"],"doi":["10.1001/jamaneurol.2025.0065"]}}